Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock new upside?

With Keytruda driving massive revenue, you need to know if Merck's oncology leadership can sustain growth amid patent cliffs. This matters for U.S. investors tracking stable dividend payers in healthcare. ISIN: US58933Y1055

Merck & Co., Inc. stands as a cornerstone in the U.S. pharmaceutical landscape, particularly for investors seeking defensive plays with robust cash flows and dividend reliability. Keytruda, its blockbuster cancer immunotherapy, generates billions in annual sales, anchoring Merck's position in oncology—a sector critical for long-term healthcare spending. You face a key question: as patent protections near expiration, can Merck's pipeline and diversification efforts deliver the next growth phase for its NYSE-listed shares.

As of: 12.04.2026

By Elena Vargas, Senior Markets Editor – Merck's blend of innovation and stability makes it a watchlist essential for dividend-focused portfolios.

Merck's Core Business Model: Oncology-Led Pharma Giant

Merck operates as a global leader in pharmaceuticals, with a business model centered on high-margin innovative drugs, vaccines, and animal health products. The company's revenue heavily relies on prescription pharmaceuticals, where breakthrough therapies like Keytruda command premium pricing in the U.S. market. This structure provides recurring revenue streams, supported by a global footprint but with significant U.S. exposure through Medicare and private insurers.

You benefit from Merck's focus on R&D investment, which sustains a pipeline of next-generation treatments. Unlike pure generics players, Merck's model emphasizes patented blockbusters, balancing risk with high returns on successful launches. This approach has delivered consistent earnings growth, making it appealing for U.S. retirement accounts prioritizing healthcare stability.

The animal health division adds diversification, tapping into steady demand from livestock and pets amid rising global protein consumption. Overall, Merck's model positions it as a resilient pharma name, less cyclical than consumer goods but sensitive to drug pricing reforms.

Products, Markets, and Competitive Position

Keytruda (pembrolizumab) dominates Merck's portfolio, approved for multiple cancer indications and holding a leading share in immuno-oncology. This PD-1 inhibitor competes with Bristol Myers Squibb's Opdivo but has outpaced it in U.S. sales due to broader labels and combination therapies. Vaccines like Gardasil for HPV prevention add high-margin growth, targeting adolescent and adult markets with strong uptake.

Merck's animal health segment, branded as MSD outside the U.S., leads in poultry and cattle vaccines, benefiting from food industry consolidation. In human pharma, the company expands into cardiometabolic and neuroscience, though these remain smaller versus oncology. Competitive edges include a vast clinical trial network and partnerships, such as with Moderna on cancer vaccines.

For U.S. readers, Merck's stronghold in Medicare Part D and hospital purchasing gives it pricing power despite Inflation Reduction Act pressures. Rivals like Pfizer and Eli Lilly challenge in specific areas, but Merck's oncology moat remains formidable, supporting premium valuations.

Why Merck Matters for Investors in the United States

As a NYSE-listed blue-chip, Merck offers U.S. investors exposure to healthcare innovation with dividend yields attractive for 401(k)s and IRAs. The company's U.S. revenue share exceeds 50%, tying its fortunes to domestic drug spending and policy shifts like the IRA's price negotiations. You gain from Merck's scale in serving 100 million+ Americans via insurance networks.

Wall Street values Merck for its defensive qualities during market downturns, as healthcare demand persists regardless of recessions. SEC filings reveal consistent share buybacks and dividend hikes, signaling board confidence in free cash flow generation. For retail investors, this translates to total returns blending growth and income.

Compared to tech-heavy portfolios, Merck provides diversification into biologics, a sector projected to grow with aging demographics. U.S. consumers benefit indirectly through faster cancer survival rates, boosting societal productivity and long-term economic value.

Industry Drivers and Strategic Outlook

Oncology market expansion, driven by personalized medicine and immunotherapies, favors Merck's expertise. Global aging populations and rising cancer incidence create tailwinds, with U.S. FDA approvals accelerating new indications. Vaccines rebound post-pandemic underscores Merck's manufacturing prowess.

Strategic initiatives include obesity drug development and AI-enhanced drug discovery, aiming to capture shares from Eli Lilly's Zepbound. Partnerships expand reach into emerging markets, hedging U.S. regulatory risks. Merck's focus on sustainability appeals to ESG-minded U.S. funds.

You should watch pipeline readouts, as successful Phase 3 trials could add tens of billions in peak sales. The company's agility in M&A, like recent bolt-ons, strengthens its position against biotech disruptors.

Analyst Views and Bank Assessments

Reputable Wall Street firms generally view Merck favorably, citing Keytruda's durability and pipeline depth as upside drivers. Institutions like JPMorgan and BofA Securities highlight the company's ability to navigate patent losses through combos and next-gen assets. Coverage emphasizes dividend safety and buyback capacity amid steady earnings.

Consensus leans positive, with many maintaining overweight or buy equivalents based on undervalued growth relative to peers. Analysts note U.S. pricing resilience despite negotiations, projecting mid-single-digit revenue growth. However, some caution on execution risks in new modalities.

Recent notes from Goldman Sachs and Morgan Stanley underscore Merck's competitive moat, recommending it for defensive healthcare allocation. These assessments, drawn from public research, align with Merck's track record of beating estimates.

Risks and Open Questions

Keytruda's patent expiry around 2028 poses the biggest risk, potentially eroding 40%+ of revenue without seamless transitions. U.S. drug pricing reforms under IRA could cap negotiation power, squeezing margins. Biosimilar competition intensifies, challenging pricing in mature markets.

Pipeline failures remain a binary risk; delays in successors like MK-1084 could stall momentum. Regulatory hurdles, including FDA scrutiny on safety, add uncertainty. Macro factors like interest rates impact R&D funding attractiveness.

Open questions include obesity program traction and animal health cyclicality from farm economics. You must monitor quarterly updates for biosimilar entry timelines and trial data.

What to Watch Next for U.S. Investors

Track Q1 earnings for Keytruda uptake in new indications and guidance on 2028 transition. FDA decisions on pipeline candidates will signal growth sustainability. Monitor Washington policy on pharma pricing for margin impacts.

Diversification progress into cardio-renal and neuroscience offers upside surprises. Dividend announcements and buyback pace reflect capital allocation discipline. Compare peer performances to gauge relative value.

For your portfolio, Merck suits long-term holds balancing growth and yield, but time entries around catalysts.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.